Form 4: Syros Pharmaceuticals CFO Jason Haas Increases Stake in Company
SEC Form 4 Filing
Syros Pharmaceuticals' Chief Financial Officer, Jason Haas, recently acquired a significant number of company shares through a series of open market purchases.
Summary
- Jason Haas, the Chief Financial Officer of Syros Pharmaceuticals, has been actively purchasing shares of the company's common stock.
- On September 10, 2024, he acquired 35,363 shares at a weighted average price of $1.5493, with individual prices ranging from $1.50 to $1.57.
- Following this transaction, his direct ownership increased to 59,915 shares.
- On September 11, 2024, Haas purchased an additional 19,293 shares at a weighted average price of $1.5781, with prices ranging from $1.55 to $1.60, bringing his total to 79,208 shares.
- A further purchase on September 12, 2024, saw him acquire 45,344 shares at a weighted average price of $1.6762, with prices ranging from $1.62 to $1.69, resulting in a total holding of 124,552 shares.
- These transactions were executed on the open market.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive due to the CFO's increased investment in the company, which suggests confidence in its future. However, it's important to consider this in the context of the company's overall financial health and market conditions.
Positives
- The CFO's decision to increase his stake in the company could be interpreted as a sign of confidence in Syros Pharmaceuticals' future prospects.
Industry Context
Insider buying is often seen as a positive signal, suggesting that a company's management believes the stock is undervalued. However, it's important to consider the overall context, including the company's financial performance and industry trends.
Stakeholder Impact
- Shareholders may view the CFO's stock purchases as a positive signal, potentially leading to increased investor confidence.
- Employees may also see this as a positive sign, indicating the leadership's belief in the company's future.
Key Dates
| Date | Description |
|---|---|
| 09/10/2024 | Jason Haas purchased 35,363 shares of Syros Pharmaceuticals common stock. |
| 09/11/2024 | Jason Haas purchased 19,293 shares of Syros Pharmaceuticals common stock. |
| 09/12/2024 | Jason Haas purchased 45,344 shares of Syros Pharmaceuticals common stock and the Form 4 was signed. |
Keywords
Syros Pharmaceuticals, SYRS, Jason Haas, insider trading, stock purchase, common stock, SEC Form 4, ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.